3月6日 - ** 专业制药公司 Scienture Holdings SCNX.O 股价盘前上涨约 60% 至 3.55 美元
** SCNX 表示 (link) 它将通过与 Kindeva Drug Delivery L.P. 合作，推出阿片类药物过量急救药物 Rezenopy 鼻用喷雾剂 10 毫克。
** Kindeva将生产和供应Rezenopy，而SCNX将拥有上市申请，并负责在美国的销售、营销和分销。
** 公司表示，Rezenopy 是目前市场上药效最强的盐酸纳洛酮。
** SCNX 在 2024 年的涨幅为 81.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.